# Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

> **NCT04588922** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sellas Life Sciences Group** · enrollment: 160 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** SLS009
- **DRUG:** venetoclax
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT04588922
- **Lead sponsor:** Sellas Life Sciences Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588922, "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04588922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*